- Alovudine
- ALVAC 1433
- AMD070
- AV-1101
- AVX754
- Azodicarbonamide (ADA)
- BMS-488043
- Brecanavir
- Buspirone hydrochloride (Buspar)
- Calanolide A
- Calcium spirulan
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvucitabine
- Etravirine
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GS 9137
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- Maraviroc
- MIV 150
- MK-0518
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- PA-457
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 542
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- T-1249
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
Extracorporeal photopheresis
Extracorporeal photopheresis is a process in which blood is drawn from a patient who has been given 8-methoxypsoralen, a light-activated photosensitising drug that is thought to bind to DNA. The red and white blood cells are separated and the white cells are passed through a sterile chamber and irradiated with ultra-violet light, then returned to the body. Approximately one-third of the individual’s white blood cells are treated in this way.
It is unclear why this might be beneficial for people with HIV. It is thought that the process may cause the drug to bind to and inactivate HIV. The treatment may also damage HIV-infected cells, making it easier for the immune system to recognise and respond to viral proteins.
Extracorporeal photopheresis is an approved treatment in the United States for cutaneous T-cell lymphoma, a tumour of the CD4 cells. A variation of the technique is used at some British specialist centres as a treatment for psoriasis. The drug is obtained on a named patient basis and given by injection, before the patient has a session on a sun bed to activate the drug in the skin.
As an HIV treatment, it is an unlicensed, experimental procedure. It has been studied in small, uncontrolled trials among people with AIDS, but no clear effects on markers such as CD4 cell count or antibody levels were seen. However, several participants reported improvements in mild symptoms such as swollen lymph nodes, fever and night sweats[1][2]. No side-effects were seen.
Ultra-violet irradiation can have side-effects including burning, development of eye cataracts, accelerated aging and the development of skin cancer. Ultra-violet light has also been shown to stimulate HIV replication in test-tube studies, but the only study in which HIV viral load was measured in people receiving ultra-violet radiation found no evidence of an increase in viral replication.
No studies of extracorporeal photopheresis are taking place in the United Kingdom and the treatment is not known to be available to people with HIV through other means.
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research
